298 related articles for article (PubMed ID: 33307734)
21. The effect of low-dose and high-dose low-molecular-weight-heparin and aspirin thromboprophylaxis on clinical outcome and mortality in critical ill patients with COVID-19: A retrospective cohort study.
Eman A; Balaban O; Süner KÖ; Cırdı Y; Şahin F; Demir G; Pekşen Ö; Musmul A; Erdem AF
Saudi Med J; 2022 Jul; 43(7):715-722. PubMed ID: 35830988
[TBL] [Abstract][Full Text] [Related]
22. Patients requiring interruption of long-term oral anticoagulant therapy: the use of fixed sub-therapeutic doses of low-molecular-weight heparin.
Malato A; Saccullo G; Lo Coco L; Caramazza D; Abbene I; Pizzo G; Casuccio A; Siragusa S
J Thromb Haemost; 2010 Jan; 8(1):107-13. PubMed ID: 19817996
[TBL] [Abstract][Full Text] [Related]
23. Heparin dosage, level, and resistance in SARS-CoV2 infected patients in intensive care unit.
Novelli C; Borotto E; Beverina I; Punzi V; Radrizzani D; Brando B
Int J Lab Hematol; 2021 Dec; 43(6):1284-1290. PubMed ID: 33855802
[TBL] [Abstract][Full Text] [Related]
24. Anticoagulation for perioperative thromboprophylaxis in people with cancer.
Matar CF; Kahale LA; Hakoum MB; Tsolakian IG; Etxeandia-Ikobaltzeta I; Yosuico VE; Terrenato I; Sperati F; Barba M; Schünemann H; Akl EA
Cochrane Database Syst Rev; 2018 Jul; 7(7):CD009447. PubMed ID: 29993117
[TBL] [Abstract][Full Text] [Related]
25. A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement.
Horbach T; Wolf H; Michaelis HC; Wagner W; Hoffmann A; Schmidt A; Beck H
Thromb Haemost; 1996 Feb; 75(2):246-50. PubMed ID: 8815569
[TBL] [Abstract][Full Text] [Related]
26. Venous thromboembolism in critically ill COVID-19 patients receiving prophylactic or therapeutic anticoagulation: a systematic review and meta-analysis.
Hasan SS; Radford S; Kow CS; Zaidi STR
J Thromb Thrombolysis; 2020 Nov; 50(4):814-821. PubMed ID: 32748122
[TBL] [Abstract][Full Text] [Related]
27. Long-term use of different doses of low-molecular-weight heparin versus vitamin K antagonists in the treatment of venous thromboembolism.
Romera-Villegas A; Cairols-Castellote MA; Vila-Coll R; Martí-Mestre X; Colomé E; Iguaz I
Ann Vasc Surg; 2010 Jul; 24(5):628-39. PubMed ID: 19932949
[TBL] [Abstract][Full Text] [Related]
28. Unfractionated heparin versus low molecular weight heparins for avoiding heparin-induced thrombocytopenia in postoperative patients.
Junqueira DR; Zorzela LM; Perini E
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD007557. PubMed ID: 28431186
[TBL] [Abstract][Full Text] [Related]
29. Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL.
Antic D; Milic N; Chatzikonstantinou T; Scarfò L; Otasevic V; Rajovic N; Allsup D; Alonso Cabrero A; Andres M; Baile Gonzales M; Capasso A; Collado R; Cordoba R; Cuéllar-García C; Correa JG; De Paoli L; De Paolis MR; Del Poeta G; Dimou M; Doubek M; Efstathopoulou M; El-Ashwah S; Enrico A; Espinet B; Farina L; Ferrari A; Foglietta M; Lopez-Garcia A; García-Marco JA; García-Serra R; Gentile M; Gimeno E; da Silva MG; Gutwein O; Hakobyan YK; Herishanu Y; Hernández-Rivas JÁ; Herold T; Itchaki G; Jaksic O; Janssens A; Kalashnikova OB; Kalicińska E; Kater AP; Kersting S; Koren-Michowitz M; Labrador J; Lad D; Laurenti L; Fresa A; Levin MD; Mayor Bastida C; Malerba L; Marasca R; Marchetti M; Marquet J; Mihaljevic B; Milosevic I; Mirás F; Morawska M; Motta M; Munir T; Murru R; Nunes R; Olivieri J; Pavlovsky MA; Piskunova I; Popov VM; Quaglia FM; Quaresmini G; Reda G; Rigolin GM; Shrestha A; Šimkovič M; Smirnova S; Špaček M; Sportoletti P; Stanca O; Stavroyianni N; Te Raa D; Tomic K; Tonino S; Trentin L; Van Der Spek E; van Gelder M; Varettoni M; Visentin A; Vitale C; Vukovic V; Wasik-Szczepanek E; Wróbel T; Segundo LYS; Yassin M; Coscia M; Rambaldi A; Montserrat E; Foà R; Cuneo A; Carrier M; Ghia P; Stamatopoulos K
J Hematol Oncol; 2022 Aug; 15(1):116. PubMed ID: 36028857
[TBL] [Abstract][Full Text] [Related]
30. Dosing of thromboprophylaxis and mortality in critically ill COVID-19 patients.
Jonmarker S; Hollenberg J; Dahlberg M; Stackelberg O; Litorell J; Everhov ÅH; Järnbert-Pettersson H; Söderberg M; Grip J; Schandl A; Günther M; Cronhjort M
Crit Care; 2020 Nov; 24(1):653. PubMed ID: 33225952
[TBL] [Abstract][Full Text] [Related]
31. The safety and efficacy of use of low-molecular-weight heparin in pediatric neurosurgical patients.
Gonda DD; Fridley J; Ryan SL; Briceño V; Lam SK; Luerssen TG; Jea A
J Neurosurg Pediatr; 2015 Sep; 16(3):329-34. PubMed ID: 26067336
[TBL] [Abstract][Full Text] [Related]
32. Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery.
Felder S; Rasmussen MS; King R; Sklow B; Kwaan M; Madoff R; Jensen C
Cochrane Database Syst Rev; 2019 Mar; 3(3):CD004318. PubMed ID: 30916777
[TBL] [Abstract][Full Text] [Related]
33. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
Míka P; Behounek J; Skoták M; Nevsímal L
Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
[TBL] [Abstract][Full Text] [Related]
34. Low molecular weight heparin versus unfractioned heparin for anticoagulation during perioperative extracorporeal membrane oxygenation: A single center experience in 102 lung transplant patients.
Gratz J; Pausch A; Schaden E; Baierl A; Jaksch P; Erhart F; Hoetzenecker K; Wiegele M
Artif Organs; 2020 Jun; 44(6):638-646. PubMed ID: 31951030
[TBL] [Abstract][Full Text] [Related]
35. Association between prophylactic low-molecular-weight heparin use in pregnancy and macrosomia: analysis of the Ottawa and Kingston birth cohort.
Lowry DE; Corsi DJ; White RR; Guo M; Lanes A; Smith G; Rodger M; Wen SW; Walker M; Gaudet L
J Thromb Haemost; 2019 Feb; 17(2):345-349. PubMed ID: 30552749
[TBL] [Abstract][Full Text] [Related]
36. Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism.
Robertson L; Strachan J
Cochrane Database Syst Rev; 2017 Feb; 2(2):CD006771. PubMed ID: 28195640
[TBL] [Abstract][Full Text] [Related]
37. Early treatment with low-molecular-weight heparin reduces mortality rate in SARS-CoV-2 patients.
DE Vito A; Saderi L; Fiore V; Geremia N; Princic E; Fanelli C; Muredda AA; Panu Napodano C; Moi G; Maida I; Fois AG; Sotgiu G; Madeddu G; Babudieri S
Panminerva Med; 2023 Sep; 65(3):286-291. PubMed ID: 35622392
[TBL] [Abstract][Full Text] [Related]
38. Low-molecular-weight heparin prophylaxis of deep vein thrombosis for older patients with restricted mobility: propensity analyses of data from two multicentre, cross-sectional studies.
Labarère J; Sevestre MA; Belmin J; Legagneux A; Barrellier MT; Thiel H; Le Roux P; Pernod G; Bosson JL;
Drugs Aging; 2009; 26(3):263-71. PubMed ID: 19358621
[TBL] [Abstract][Full Text] [Related]
39. [Prevention of pulmonary embolism].
Minar E
Acta Med Austriaca; 1992; 19(1):25-34. PubMed ID: 1316706
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of venous thromboembolism prophylaxis with fondaparinux or low molecular weight heparin in a large cohort of consecutive patients undergoing major orthopaedic surgery - findings from the ORTHO-TEP registry.
Donath L; Lützner J; Werth S; Kuhlisch E; Hartmann A; Günther KP; Weiss N; Beyer-Westendorf J
Br J Clin Pharmacol; 2012 Dec; 74(6):947-58. PubMed ID: 22515679
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
